Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Non-Current Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Total Non-Current Liabilities data on record, last reported at $13.3 million in Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities fell 4.98% to $13.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $13.3 million, a 4.98% decrease, with the full-year FY2025 number at $17.1 million, down 2.29% from a year prior.
  • Total Non-Current Liabilities reached $13.3 million in Q1 2026 per FULC's latest filing, down from $17.1 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for FULC hit a ceiling of $34.3 million in Q2 2022 and a floor of $13.3 million in Q1 2026.
  • A 5-year average of $21.0 million and a median of $20.9 million in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: grew 17.41% in 2022, then dropped 29.63% in 2025.
  • Tracing FULC's Total Non-Current Liabilities over 5 years: stood at $27.5 million in 2022, then dropped by 19.03% to $22.3 million in 2023, then dropped by 21.6% to $17.5 million in 2024, then fell by 2.29% to $17.1 million in 2025, then decreased by 22.34% to $13.3 million in 2026.
  • Business Quant data shows Total Non-Current Liabilities for FULC at $13.3 million in Q1 2026, $17.1 million in Q4 2025, and $16.3 million in Q3 2025.